We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$1.54B
AUM Growth
+$254M
Cap. Flow
+$211M
Cap. Flow %
13.67%
Top 10 Hldgs %
62.61%
Holding
55
New
12
Increased
18
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.4M
2
TGTX icon
TG Therapeutics
TGTX
+$28.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$28.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$26.8M
5
AZN icon
AstraZeneca
AZN
+$25.3M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$89.4M
2
TSRO
TESARO, Inc.
TSRO
+$25.2M
3
PCRX icon
Pacira BioSciences
PCRX
+$18.3M
4
MDCO
Medicines Co
MDCO
+$13.1M
5
DBVT
DBV Technologies
DBVT
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 76.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVEO
26
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$11.2M 0.72%
400,689
-79,936
-17% -$2.48M
CASC
27
DELISTED
Cascadian Therapeutics, Inc.
CASC
$9.2M 0.6%
2,485,272
+664,024
+36% +$2.72M
ALIM
28
DELISTED
Alimera Sciences
ALIM
$8.3M 0.54%
416,105
– –
IMMU
29
CALL
DELISTED
Immunomedics Inc
IMMU
$8.22M 0.53%
875,000
– –
AGEN
30
Agenus
AGEN
$276M
$7.95M 0.52%
124,295
-1,019
-0.8% -$77.8K
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$7.32M 0.47%
+396,635
New +$5.84M
BDSI
32
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$7.29M 0.47%
+2,469,488
New +$6.83M
LUMO
33
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$6.45M 0.42%
+88,379
New +$7.31M
VRAY
34
DELISTED
ViewRay, Inc.
VRAY
$5.82M 0.38%
+730,161
New +$5.84M
GYRE icon
35
Gyre Therapeutics
GYRE
$629M
$5.46M 0.35%
+53,333
New +$2.72M
VIVE
36
DELISTED
VIVEVE MED INC
VIVE
$5.13M 0.33%
1,033
– –
VCYT icon
37
Veracyte
VCYT
$4.45B
$4.91M 0.32%
752,455
-184,454
-20% -$1.37M
INCY icon
38
Incyte
INCY
$25.8B
$4.74M 0.31%
+50,000
New +$5.23M
FENC icon
39
Fennec Pharmaceuticals
FENC
$335M
$2.73M 0.18%
206,000
+139,334
+209% +$1.39M
CLLS
40
Cellectis
CLLS
$288M
$2.28M 0.15%
78,289
– –
FOLD
41
CALL
DELISTED
Amicus Therapeutics
FOLD
$1.76M 0.11%
1,500,000
-1,500,000
-50% -$20.6M
BCRX icon
42
BioCryst Pharmaceuticals
BCRX
$2.42B
$1.67M 0.11%
340,821
-1,437,704
-81% -$6.96M
OTLK icon
43
Outlook Therapeutics
OTLK
$187M
$889K 0.06%
4,272
– –
CLVS
44
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$264K 0.02%
+675,000
New +$47.2M
ARRY
45
CALL
DELISTED
Array Biopharma Inc
ARRY
$216K 0.01%
75,000
-425,000
-85% -$4.83M
BMRN icon
46
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$135K 0.01%
+300,000
New +$26.1M
MGNX icon
47
CALL
MacroGenics
MGNX
$233M
$37K ﹤0.01%
+14,500
New +$271K
ONSIW
48
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$7K ﹤0.01%
233,333
– –
ONSIZ
49
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$5K ﹤0.01%
233,333
– –
DBVT
50
DBV Technologies
DBVT
$813M
– –
-19,360
Closed -$8.22M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Avoro Capital Advisors held 55 positions worth $1.54B, up 20% from $1.29B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Avoro Capital Advisors deployed $211M of net new capital in Q4 2017, opening 12 new positions and adding to 18 existing holdings. Its largest new stake was TG Therapeutics: 3,294,463 shares worth $27M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 67% a quarter earlier.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $18.3M trimmed.

  • Avoro Capital Advisors's largest Q4 2017 buy was TG Therapeutics: 3,294,463 shares worth $27M.
  • Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $51.4M increase.
  • Avoro Capital Advisors's biggest Q4 2017 reduction was Pacira BioSciences, cutting an estimated $18.3M.
  • Avoro Capital Advisors fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $89.4M.
  • Avoro Capital Advisors's ten largest holdings make up 63% of its $1.54B portfolio in Q4 2017.
  • Avoro Capital Advisors opened 12 new positions and closed 5 in Q4 2017.
  • Avoro Capital Advisors's portfolio value rose 20% quarter-over-quarter to $1.54B.

Based on Avoro Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.